Clay Siegall is the President and founder of Seattle Genetics, a company situated in Seattle. The firm focuses on developing drugs for various diseases. The firm was founded in the year 1998 and has since then successfully penetrated the therapy industry. This can be attested by the firm’s approval of the FDA antibody medicine which it developed. The firm has also gone ahead and partnered with various stakeholders such as Pfizer, Genentech, and Bayer and as a result developed more than 20 drugs.
According to his interview with Inspirery, Dr. Siegall says that with the new technology today, the old remedies of curing cancer will soon be a thing of the past. He reveals that they are working towards developing more effective drugs that will work miracles. When asked what inspired him to join the medicine world, Dr. Clay Siegall says that since he was a little boy, he was always interested in medicine. The simple thought of involving technology to cure a disease and restoring good health was quite fascinating to him. He continues to say that while undertaking his studies, he almost lost a loved one as a result of chemotherapy. The ordeal gave him a wake-up call, and he realized that there were better ways of treating the deadly disease.
Dr. Siegall reveals that one of the many ways on how they make money is through selling their drugs. However, he says that they encounter various setbacks such as incurring the losses when a drug fails to be FDA-approved. He reveals that their success secret was having on board talented sales people that introduced the drug to the market. Dr. Siegall believes that they are quite successful as a result of their hard work.
About Dr. Clay Siegall
Dr. Siegall graduated from the University of Maryland with a B.S in Zoology. He later enrolled at George Washington University and attained a Ph.D. in genetics. He co-founded Seattle Genetics in the year 1998 and is the firm’s CEO, President, and chairs the Board members. He brings to the table over 19 years of experience in the industry.
Through his leadership, the company has been able to generate about $675 million worth of funds from both private and public financing. Before Seattle Genetics was founded, Dr. Siegall served at Bristol-Myers Squibb. Other institutions where Dr. Siegall worked include National Institutes of Health and the National Cancer Institute. Interesting to note, Dr. Siegall has many publications to his name and holds about 15 patents. He is also a Board Director for Alder Bio-pharmaceuticals.